ArticleJournal of molecular neuroscience : MN2000
VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress.
Article in Journal of molecular neuroscience : MN, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01056965 (A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies
Who cites it
27 citing papers in PubMed, 78 citations in OpenAlex.
- Oxidative Stress Promotes Axonal Atrophy through Alterations in Microtubules and EB1 Function.Aging and disease · 2024Article
- 18Beta-Glycyrrhetinic Acid Attenuates HAntioxidants (Basel, Switzerland) · 2024Article
- The role of vasoactive intestinal peptide (VIP) in atropine-related inhibition of the progression of myopia.BMC ophthalmology · 2024Article
- Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.International journal of molecular sciences · 2022Review
- Retinoprotective Effects of TAT-Bound Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase Activating Polypeptide.Journal of molecular neuroscience : MN · 2019Article
- Microtubule stabilising peptides rescue tau phenotypes in-vivo.Scientific reports · 2016Article
- Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.Journal of molecular neuroscience : MN · 2016Review
- Protein profiling reveals antioxidant and signaling activities of NAP (Davunetide) in rodent hippocampus exposed to hypobaric hypoxia.Journal of molecular neuroscience : MN · 2014Article
- Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic death.Journal of molecular neuroscience : MN · 2014Article
- Experimental methods for testing the effects of neurotrophic peptide, ADNF-9, against alcohol-induced apoptosis during pregnancy in c57bl/6 mice.Journal of visualized experiments : JoVE · 2013Article
- Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.The EPMA journal · 2010Article
- Nur(R1)turing a notion on the etiopathogenesis of Parkinson's disease.Neurotoxicity research · 2009Article
- VIP, from gene to behavior and back: summarizing my 25 years of research.Journal of molecular neuroscience : MN · 2008Article
- Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL.Journal of molecular neuroscience : MN · 2006Article
- PolyADP-ribosylation is involved in neurotrophic activity.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2005Article
- Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures.Journal of molecular neuroscience : MN · 2005Article
- NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).CNS drug reviews · 2005Review
- Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.Neuron glia biology · 2004Article
- NAP mechanisms of neuroprotection.Journal of molecular neuroscience : MN · 2004Article
- Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection.Journal of molecular neuroscience : MN · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress is a common associative mechanism that is part of the pathogenesis of many neurodegenerative diseases. Vasoactive intestinal peptide (VIP) is a principal neuropeptide associated with normal development and aging. We have previously reported that VIP induced the secretion of proteins from glial cells, including the novel survival-promoter: activity-dependent neurotrophic factor (ADNF). ADNF-9, a nine amino acid peptide derived from ADNF, protects neurons from death caused by various toxins. In the present study, we examined the neuroprotective effect of VIP against oxidative stress in a pheochromocytoma cell line (PC12). In addition, a lipophilic derivative of VIP, Stearyl-Nle17-VIP (SNV), and two femtomolar-acting peptides: ADNF-9 and a 70% homologous peptide to ADNF-9, NAP were tested as well. PC12 cells were treated with 100 microM H2O2 for 24 h resulting in a reduction in cell survival to 35-50% as compared to controls. Addition of VIP or SNV prior and during the exposure to100 microM H2O2 increased cell survival to 80-90% of control values. Culture treatment with ADNF-9 or NAP in the presence of 100 microM H2O2 increased cell survival to 75-80% of control values. Messenger RNA expression analysis revealed that incubation with VIP resulted in a twofold increase in VIP mRNA, whereas NAP treatment did not cause any change in VIP expression, implicating different mechanisms of action. Furthermore, addition of an ADNF-9 antibody prevented the ability of VIP to protect against oxidative stress, suggesting that VIP protection is partially mediated via an ADNF-like protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.